Table 2.
Characteristics of patients with prostate cancer by study*
| Study (reference) | Time from blood collection to diagnosis | Age at diagnosis | Date of diagnosis | Stage of disease | Grade of disease | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|||||||||
| <3 y | 3–6 y | ≥7 y | <60 y | 60–69 y | ≥70 y | Pre-1990 | 1990–1994 | 1995 onward | Localized | Advanced | Low | High | |
| ATBC (17) | 37.1 | 61.2 | 1.7 | 22.4 | 57.8 | 19.8 | 37.9 | 62.1 | 0.0 | 61.2 | 38.8 | 53.6 | 46.4 |
| BLSA (11,24) | 4.6 | 14.8 | 80.7 | 4.0 | 30.7 | 65.3 | 29.6 | 44.3 | 26.1 | 77.3 | 22.7 | 64.7 | 35.3 |
| CARET (21) | 55.3 | 39.7 | 5.0 | 13.7 | 54.0 | 32.3 | 5.3 | 39.7 | 55.0 | 68.5 | 31.5 | 59.8 | 40.2 |
| CLUE (9,10) | 16.1 | 25.0 | 58.9 | 8.9 | 39.5 | 51.6 | 100.0 | 0.0 | 0.0 | 75.3 | 24.7 | 71.4 | 28.6 |
| EPIC (27) | 42.5 | 52.9 | 4.7 | 19.1 | 63.1 | 17.7 | 0.0 | 0.9 | 99.1 | 68.7 | 31.3 | 67.7 | 32.3 |
| FMC (18) | 6.0 | 16.9 | 77.1 | 10.2 | 33.7 | 56.0 | 87.4 | 12.7 | 0.0 | N/A | N/A | N/A | N/A |
| HHS (NBSBWG) (22) | 2.4 | 15.5 | 82.1 | 32.1 | 67.9 | 0.0 | 21.4 | 54.8 | 23.8 | 62.1 | 37.9 | N/A | N/A |
| HPFS (25) | 45.3 | 54.4 | 0.3 | 13.6 | 38.3 | 48.1 | 0.0 | 11.3 | 88.7 | 82.9 | 17.1 | 60.4 | 39.6 |
| JACC (23) | 17.5 | 52.5 | 30.0 | 0.0 | 35.0 | 65.0 | 5.0 | 50.0 | 45.0 | N/A | N/A | N/A | N/A |
| Janus (16) | 13.3 | 16.7 | 70.0 | 8.3 | 53.3 | 38.3 | 53.3 | 46.7 | 0.0 | N/A | N/A | N/A | N/A |
| Janus (NBSBWG) (22) | 1.1 | 4.2 | 94.7 | 20.9 | 69.8 | 9.2 | 22.3 | 54.7 | 23.0 | 74.9 | 25.1 | 76.0 | 24.0 |
| JHCS (7,14) | 6.4 | 18.6 | 75.0 | 1.6 | 30.3 | 68.1 | 90.4 | 9.6 | 0.0 | 65.4 | 34.6 | N/A | N/A |
| KPMCP (12) | 17.8 | 17.8 | 64.4 | 0.0 | 6.7 | 93.3 | 100.0 | 0.0 | 0.0 | 61.9 | 38.1 | 90.0 | 10.0 |
| MCCS (26) | 29.8 | 41.0 | 29.2 | 11.3 | 55.9 | 32.8 | 0.0 | 17.4 | 82.6 | 91.3 | 8.7 | 62.6 | 37.4 |
| NSHDC (22) | 27.1 | 49.6 | 23.2 | 17.1 | 77.5 | 5.4 | 0.0 | 10.4 | 89.6 | 80.9 | 19.1 | 84.9 | 15.1 |
| PHS (13) | 9.2 | 21.4 | 69.4 | 11.7 | 48.4 | 39.9 | 31.5 | 64.8 | 3.7 | 69.1 | 30.9 | 65.7 | 34.3 |
| ProtecT (28) | 100.0 | 0.0 | 0.0 | 29.6 | 69.9 | 0.6 | 0.0 | 0.0 | 100.0 | 73.9 | 26.1 | 70.5 | 29.5 |
| RBS (8) | 15.5 | 35.5 | 49.1 | 1.8 | 17.3 | 80.9 | 30.9 | 37.3 | 31.8 | N/A | N/A | N/A | N/A |
Data are percentages of case patients among those with a known value of the characteristic. Percentages may not add to 100 due to rounding. Stage and grade of disease were unknown for some case patients, and the percentages displayed are among those with known information. ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA = Baltimore Longitudinal Study of Aging; CARET = Carotene and Retinol Efficacy Trial; CLUE = CLUE Study, Washington County, Maryland; EPIC = European Prospective Investigation into Cancer and Nutrition; FMC = Finnish Mobile Clinic Health Examination Survey; HHS = Helsinki Heart Study; NBSBWG = Nordic Biological Specimen Biobank Working Group; HPFS = Health Professionals Follow-up Study; JACC = Japan Collaborative Cohort Study; Janus = Janus Serum Bank; JHCS = Japan–Hawaii Cancer Study; KPMCP = Kaiser Permanente Medical Care Program; MCCS = Melbourne Collaborative Cohort Study; NSHDC = Northern Sweden Health and Disease Cohort; PHS = Physicians’ Health Study; ProtecT = Prostate Testing for Cancer and Treatment; RBS = Rancho Bernardo Study; N/A = data not available for this study.